An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy

NCT05540964 · clinicaltrials.gov ↗

UNKNOWN

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV

Interventions

OTHER: Antiretroviral Therapy Interruption(ATI)

Sponsor

American Gene Technologies International Inc.